Å·ÃÀAV

Dr. Jayanta Haldar is an Associate Professor at New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore, India. He is also associated with the School of Advanced Materials (SAMat). Prof Haldar did his masters & PhD from IISc Bangalore and Postdoc from Massachusetts Institute of Technology, USA. His research interests are towards the development of molecular strategies for the prevention and treatment of infectious diseases. He has published many international peer-reviewed papers, book chapters and review articles and has also got many patents in his name.

His research work also has been featured in leading print and television media. He has been awarded as a Ramanujan Fellow from the Department of Science and Technology, Government of India, in 2010. Inventions from his lab received two Biotechnology Industry Research Assistance Council (BIRAC-GYTI) awards in 2015 and 2016 and received two Gandhian Young Technological Innovation appreciation awards in 2015 and 2016. He is an editorial board member of the journals “Microbial Pathogenesis” and “Å·ÃÀAV Medicinal Chemistry” He also serves as an Editorial Advisory Board Members of journals such as Biomacromolecules and ACS Infectious Diseases. He has been awarded CDRI-Awards 2017 for Excellence in Drug Research and received Chemical Research Society of India (CRSI) Bronze Medal 2017 and Sheik Saqr Career Award Fellowship in 2018. Dr. Haldar has also been awarded for Indo-US virtual Newtworks for Covid-19 program by Indo-US Science and Technology Forum in 2020. 

Katie obtained her undergraduate Masters degree and PhD from the University of Bristol, UK. Currently based in Cambridge, she has over six years of experience at the Å·ÃÀAV working on a variety of different journals, including as Executive Editor of the physical chemistry and sustainability journal portfolio and Managing Editor of Å·ÃÀAV Advances.
As Executive Editor of the organic chemistry journal portfolio at the Å·ÃÀAV, Katie leads 4 Å·ÃÀAV titles: OBC, Molecular Omics, Å·ÃÀAV Medicinal Chemistry and Natural Product Reports (NPR). 

Dr. Venkata Palle is currently Senior Vice President of Discovery Research at Lupin Pharma. Prior to joining Lupin, Dr. Palle played a leading role in Medicinal Chemistry in the drug discovery efforts at Advinus Therapeutics (Pune, India), Ranbaxy Laboratories (Gurgoan, India), CV Therapeutics (Now Gilead Sciences, Palo Alto, CA, USA) and NeXstar Pharmaceuticals (Boulder, CO, USA). He is co-inventor of currently marketed drug Regadenoson (LexiScan). He has also developed a number of drug candidates that are in various stages of clinical development. Dr.Palle has more than hundred granted US patents and over fifty publications to his credit. He received Ph.D. in Organic Chemistry from Indian Institute of Science (Bangalore) and conducted post-doctoral work at the University of Rhode Island (Kingston, Rhode Island, USA)